anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses water soluble medicament sustained-release tablets, which comprise the following components in part by weight: water soluble medicament 1-30, octadecanol 5-70, Eudragite L 100-55 2-50, talcpowder 2-30 and lactose 2-30. The water soluble medicament may be galanthamine hydrobromide, captopril, metoprolol tartaric acid or pseudoephedrine hydrochloride. In the invention, the octadecanol serving as a hydrophobic auxiliary material and the Eudragite L 100-55 sreving as a water soluble polymer auxiliary are adopted, so the release speed of the medicament can be controlled properly. The Eudragite L 100-55 is insoluble in gastric juice, but dissolves in duodenal juice to make high-viscosity sticky liquid, and thus the release and diffusion speed of the medicament can be reduced. The talcpowder which is a hydrophilic matter insoluble in water plays a porogen role in the sustained-release tablets. In the invention, the release speed of the medicament is regulated by regulating the mixing ratio of the medicament to the auxiliary material. Thus, the release speed of an active medicament is controlled.
FIELD: medicine. ^ SUBSTANCE: invention relates to field of medicine. Claimed invention relates to method and composition for treatment of central nervous system (CNS) disorder by intranasal application of compounds, which induce RNA interference. Composition by the invention contains molecules of short interfering nucleic acids (siPHK). Disorder is selected from dementia, Alzheimer's disease, Huntington's disease and/or Parkinson's disease, as well as congenital diseases associated with mutations in CNS genes. According to the invention method includes introduction to patient in case of necessity of efficient amount of one or more siPHK in accordance with the invention. ^ EFFECT: invention ensures suppression of expression of target genes, connected with changed CNS states. ^ 20 cl, 4 ex, 8 dwg
Most hospitals in Pakistan still do not have a policy of early laparoscopic cholecystectomy in acutely inflamed gallbladder, partly because of feared higher conversion rates to open procedure and presumed increased risk of complications. There are fewer local studies to elaborate the role of drain after laparoscopic cholecystectomy for acutely inflamed gallbladder. This study was conducted to analyze the role of routine use of drains after laparoscopic cholecystectomy for acutely inflamed gallbladder. Does it offer any advantage in detecting bile leak or bleeding. Also to prove that placing drains prolongs the hospital stay and increases postoperative pain in comparison to patients in whom drain is not placed.

After being informed about the study and the potential risks, all patients giving written informed consent, underwent laparoscopic cholecystectomy using conventional 4 port method. Patients were divided in two groups by lottery method. Group A - no drain group and Group B - drain group. Post operatively parameters of pain and total hospital stay were assessed and analysed.
Pediatric subjects \> = 6 months to \< 12 months will receive a starting dose of 0.4mg/kg administered subcutaneously (SC) every 2 weeks (Q2W) for 48 weeks with the option of the dose to be increased to 0.8mg/kg upon recommendation of the Data Safety Management Board (DSMB). The dose can be either increased up to a maximum of 2 mg/kg or decreased to 0.2 mg/kg depending on serum phosphate response. Upon recommendation of the DSMB subjects \< 6 months can then start at 0.4mg/kg starting dose administered subcutaneously (SC) every 2 weeks (Q2W) for 48 weeks with the option to be increased to 0.8mg/kg upon recommendation of the DSMB and can be either increased up to a maximum of 2 mg/kg or decreased to 0.2 mg/kg depending on serum phosphate response.
Children will be treated with a simplified protocol prescribing 2 sachets of RUTF to children admitted with a MUAC\<115mm or edema and 1 sachet to children with MUAC 115-124mm. Children admitted with a MUAC\<115mm or edema will be transitioned to receive 1 sachet of RUTF once they have reached a MUAC\>=115mm for 2 consecutive visits. Visit frequency will be weekly for children in the "severe phase" and fortnightly for children in the "moderate" phase.
The invention discloses a pharmaceutical composition for the treatment of glaucoma. The composition includes brimonidine or a pharmaceutically acceptable salt thereof and at least one medicament for lowering intraocular pressure and optionally at least one pharmaceutically acceptable carrier. The active ingredients in all cases are in free form or in the form of pharmaceutically acceptable salt. The composition is for simultaneous, separate or sequential usage; and preferably, the medicament for lowering intraocular pressure is lutein. The invention has the advantage that medicaments with different mechanisms of action area combined to give full play to complementary synergistic effects of the medicaments and to reduce adverse reactions associated with the increase of a certain dose. The pharmaceutical composition can relieve symptoms in a short period of time, and can be effective in the treatment of glaucoma.
Controls will receive baseline EEG and MRI, screening questionnaires and intake interview. They will not participate in therapy but complete weekly symptom measures and a second EEG/MRI session 12 weeks after baseline. Control participants will be compared with social anxiety participants to determine differences in neuro-markers at baseline and over follow-up.
The invention relates to a means, in the form of a tablet, capsule, powder and so on, for reducing the "sugars" in the body. The means according to the invention has the characteristic that this means is made up of vitamin C, vitamin B1, vitamin B2, vitamin B6, vitamin B12, nicotinamide (B3), natural minerals and trace elements, folic acid and amino acids. Especially good results are achieved according to the invention when the vitamins, amino acids, natural minerals and trace elements are present in the means in the right quantity and have preferably been processed into tablets of about 500 mg. Using a hand refractometer, ATAGO brand, type N1, brix range 0-32%, the sugar content of food etc. was measured without addition of the inventive means and after addition of the inventive means, and a significant difference was observed. The present invention further embraces a method for the preparation of the tablets, with the characteristic that vitamin C, vitamin B1, vitamin B2, vitamin B6 and vitamin B12 are first thoroughly mixed with each other, followed by the mixing of folic acid, amino acids, natural minerals and trace elements and nicotinamide, after which the mixtures so obtained, as well as the other constituents, are thoroughly mixed with each other, providing a multi-vitamin mixture which in turn is mixed with fillers, if there are any, and which mixture is finally processed into tablets of about 500 mg.
Colorectal neoplasia prevalence was 35 000 for a total number of 278 000 cancers in France during 2000. Treatment of these cancers is based on local extension especially in the digestive tract (stade) and on co-morbidities of the patient. There are many advantages to treat these cancers at an early stade (involving mucosa or superficial submucosa), since they are associated with a better prognosis with a lower cost-effectivness ratio. Indeed, in 2003 mean cost of treatment of colorectal cancer during the first year following diagnosis was 24 000 €, whereas it was only 18 000 € for early stade and up to 36 000 € for the most advanced stade. Transversal (1 week) and national survey of the French society of endoscopy (SFED) during 8 years demonstrated that among 1 millions of endoscopies (3/4 being performed with anesthesia), 8000 were performed for endosocpic treatment of early digestive cancers by endoscopic mucosal resection (EMR) or more recently by endoscopic submucosal dissection (ESD). One of the problems to diffuse these endoscopic treatments is the multiple tools required to endotherapy, and the fact that this treatment is time-consuming, whereas a simple ablation of polyps (polypectomy) smaller than 1.5 cm needs only 5 to 10 minutes. For exemple, endotherapeutic tools for polypectomy (one needle and one polypectomy loop) costs 180 € and occasionally required a couple of clips when rare (1%) hemorrhage or exceptional (1p1000) perforation occurred. Conversely, endotherapy tools for ESD of early mucosal or submucosal digestive cancers larger than 1.5 cm up to 4-5 cm, costs 1500 €, including needles, submucosal injected products, hook-knife, insulinated-knife and coagulation rasper. So, the recent T2A codification gathers these two kinds of endoscopic treatment under the same code, whatever the size of the lesion, whereas costs of tools required for their treatment are notably different especially when there are performed for inpatients hospitalized less that 2 days which is only charged 480 € added of 192 € and 53€ for salary in private exercise or 914 € in public hospital, by the national and public healthcare system. Beside the expertise required for EMR and ESD of larger early cancers, this cost does not invite to increase the frequency of EMR or ESD, taking into account that this treatment is better practised by two simultaneous endoscopists, one of them manipulating the endoscope en endotherapy tools.
Systems and methods for determining myocardium strain and intracardiac blood flow data of the heart are provided. Input medical imaging data of a heart of a patient is received. At least one of extracted myocardium strain data of the heart and extracted intracardiac blood flow data of the heart is determined from the input medical imaging data. At least one of predicted myocardium strain data of the heart and predicted intracardiac blood flow data of the heart is determined based on the at least one of the extracted myocardium strain data and the extracted intracardiac blood flow data using a model of the heart. The model of the heart jointly models myocardium strain of the heart and intracardiac blood flow of the heart. The at least one of the predicted myocardium strain of the heart and the predicted intracardiac blood flow of the heart is output.
The single blinded, randomised study is planned to commence in October 2014 after obtaining Research Ethics Committee and NHS Research and Development approval. A target of 20 participants with symptomatic paroxysmal AF will be recruited. All participants will be blinded and randomised to AF ablation only or AF ablation + ROX coupler implant. All participants will have right and left heart catheterisation prior to AF ablation +/- ROX coupler insertion. Participants will be followed up 6 weeks, 3, 6 months and 12 months after the ablation. The study will take place at Eastbourne District General. The study duration per patient is 13months. The overall study duration will be 18 months.
Alclometasone dipropionate cream and ointment may be used with caution in pediatric patients 1 year of age or older, although the safety and efficacy of drug use for longer than 3 weeks have not been established. Use of alclometasone dipropionate cream and ointment is supported by results from adequate and well-controlled studies in pediatric patients with corticosteroid-responsive dermatoses. Since the safety and efficacy of alclometasone dipropionate cream and ointment have not been established in pediatric patients below 1 year of age, its use in this age-group is not recommended. Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression and Cushing syndrome when they are treated with topical corticosteroids. They are therefore also at greater risk of adrenal insufficiency during and/or after withdrawal of treatment. Adverse effects, including striae, have been reported with inappropriate use of topical corticosteroids in infants and children. Pediatric patients applying alclometasone dipropionate cream or ointment to >20% of the body surface area are at higher risk for HPA axis suppression. 

HPA axis suppression, Cushing syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in pediatric patients include low plasma cortisol levels and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. 

Alclometasone dipropionate cream or ointment should not be used in the treatment of diaper dermatitis.
PROBLEM TO BE SOLVED: To obtain the subject compound enabling the protection of mitochondria exposed to the stress of anoxia and the recovery of ATP synthesis of an oxygen-deficient organ and capable of passing through the blood-brain barrier. SOLUTION: This compound is expressed by formula I (R1 is a straight or branched chain 1-6C alkyl; X is O or S; R2 is straight or branched chain 1-8C alkyl, a straight or branched chain 1-6C alkoxy, phenyl, a 3-7C cycloalkyl, etc.; R3 is H, a 3-7C cycloalkyl, formyl, phenyl, etc.), its isomer or an addition salt with a pharmaceutically permissible acid or base, e.g. N-(3,4-dimethoxy-2-E- phenylcyclopropylcarbonyloxy)benzyl-N'-ethylpiperazine dihydrochloride. The compound of formula I can be produced e.g. by reacting the starting substance of formula II with a substituted piperazine of formula III the presence of formaldehyde and then reacting with a carboxylic acid, etc., of the formula R2 CO2 H.
The present invention relates to the fields of chemistry and pharmaceuticals. Embodiments of the invention provide cellulose esters useful for inhibiting solution crystallization of drugs. Specific polymers of the invention include cellulose esters of formula (I) : wherein n of the ω-carboxyalkanoyl group, Formula (II), is 3, 4, 6, or 8 to provide a ω-carboxyalkanoyl group chosen from succinoyl, glutaroyl, adipoyl, sebacyl, and suberyl groups; and wherein R is chosen from : a hydrogen atom; and an alkanoyl group chosen from acetyl, propionyl, butyryl, valeroyl, hexanoyl, nonanoyl, decanoyl, lauroyl, palmitoyl, and stearoyl groups; wherein there is a total degree of substitution of the alkanoyl group and the ω-carboxyalkanoyl group of at least 2.0; and wherein the polymer comprises m repeating units where n = 1 to 1,000,000, or 10 to 100,000, or 100 to 1,000, such as 1 to 6,000. Embodiments further include compositions comprising cellulose esters and poorly water-soluble drugs, which compositions exhibit greater solubility and stability in solution as compared to the drugs alone. Drugs that can be used in combination with such polymers include but are not limited to ritonavir, efavirenz, etravirine, celecoxib, clarithromycin, curcumin, ellagic acid, quercetin, naringenin, and resveratrol. Methods for making and using the compounds and compositions are also included within the scope of the invention.
This cohort is a prospective cohort to develop a risk prediction model. This cohort include patients who underwent staging operation or debulking operation for epithelial ovarian cancer and are planned to receive ajuvant chemotherapy with paclitaxel/carboplatin up to 6 cycles.
PROBLEM TO BE SOLVED: To prepare an antidemential substance having antidemential action by including an extract prepared through the extraction treatment of jin zhencai as an active principle. SOLUTION: This antidemential substance is prepared by including an extract prepared through the extraction treatment of jin zhencai as an active principle. The extract from jin zhencai is prepared by blending 1 pt.wt. fresh jin zhenkai with about 4 pts.wt. water and by subjecting the mixture to extraction treatment in hot water at about 80 deg.C for 2-4 h. The jin zhencai extract has action enhancing resistance to stress, too, and is useful as a substance having action enhancing resistance to stress, too. The jin zhencai is prepared by drying the bud of yellow day lily belonging to lilies, is also called huang hua cai, the bud of which is steamed and dried, and is used as a food material.  Jin zhencai is known that it includes an ingredient having efficacy as a medicine against sleeplessness, anemia, poor circulation, shoulder stiffness, eyestrain, liver function failure, swelling or the like until now, but was not known that it has antidemential action (preventive action of dysmnesia) and action enhancing resistance to stress, too.
The tDCS sessions will be conducted with an intensity of 2mA, utilizing the anodic electrode positioned over the cerebellar region and the cathodic electrode over the thoracic region of the spinal cord (approximately at vertebra T11). These sessions will be integrated into a gait and postural control training protocol, which will progressively increase in difficulty over 4 consecutive weeks on weekdays, excluding weekends. A total of 20 sessions will be administered, each lasting approximately 30 minutes. During each session, the electrodes will be placed, and participants will perform a single leg test on each side of the body. The exercise protocol will then be executed while the tDCS is applied, lasting for 20 minutes. Following the exercise, the single-leg test will be repeated, and the electrodes will be removed.
FIELD: biotechnology. SUBSTANCE: strain Morganella morganii N 2223 is isolated from sick child with enteric infection and deposited in Collection of The State Scientific-Research Institute of standardization and control of medicinal and biological preparations at number 240. Strain of bacterium Morganella morganii GISK 240 is a producer of thermolabile enterotoxin. Strain shows the enhanced toxin-producing capability. Strain is resistant to penicillin, tetracycline, gentamycin, streptomycin, methicillin. Invention can be used for production of thermolabile enterotoxin and anatoxin from Morganella morganii at vaccines production. EFFECT: strain indicated above, enhanced production of toxins. 1 tbl
In spite of existing work studying rTMS as a treatment modality in schizophrenia, there are no studies that have examined the effects of precuneus directed rTMS on either EM deficits or the neurocircuitry subserving EM in schizophrenia. It is also important to note that the vast majority of studies using rTMS in schizophrenia have examined chronic populations where confounds associated with prolonged duration of illness may be present. Early Phase Psychosis (EPP) is a desirable population to study because these individuals tend to have fewer psychiatric and physical comorbidities and less antipsychotic drug exposure, all of which are factors that may confound investigations of new treatment interventions for this illness. In light of the significant unmet medical need associated with schizophrenia and the grave clinical effect of disrupted EM in the illness, rTMS modulating the precuneus, and potentially EM circuitry, represents an unexplored and potentially novel potential treatment option.

This study proposes to combine functional magnetic resonance imaging (fMRI) with inhibitory Low Frequency (LF) (1 Hz) and excitatory High Frequency (HF) (20 Hz) rTMS protocols to interrogate the effects of rTMS targeting the precuneus on: 1) precuneus activation during EM task performance; 2) functional connectivity between the precuneus and key EM circuitry, specifically the Dorsolateral Prefrontal Cortex (DLPFC), Anterior Cingulate Cortex (ACC), and hippocampus and 3) performance during an in-scanner scene encoding and recognition EM task. This study will provide vital preliminary data on target engagement informing future clinical trials seeking to utilize rTMS to treat EM impairment in schizophrenia. This is an important population for study because if effective, rTMS may represent a novel treatment for EM deficits in schizophrenia. This study will also seek to refine the understanding of the brain circuitry that mediates the potential pro-EM effects of rTMS through the use of fMRI at baseline and following the course of rTMS administration.
Testosterone is a substance commonly abused in the sporting world despite being banned by all American sports leagues, international federations, and the World Anti-Doping Agency. Current methods employed to detect exogenously administered testosterone include direct detection using isotope ratio mass spectrometry (IRMS) and indirect detection using the athlete biological passport (ABP). However, different formulations of testosterone (oral, transdermal, sublingual, etc) are expected to result in characteristic IRMS profiles, affect the ABP readings in unique ways, and differ in their windows of detection. In 2014, a new formulation of testosterone, Natesto, which is administered intranasally, was FDA approved. Though only approved for medical use, it is expected athletes may use this product, and its effect on steroid doping markers has yet to be determined. Characterization of this detection profile is necessary for confirmation of the exact product being administered in an anti-doping setting. In this study, the investigators aim to understand the effects on the steroid doping profile following a single administration of Natesto to healthy, active volunteers. Windows of detection will be determined for the standard dosing of Natesto, and the effects on ABP markers and IRMS profiles will also be established.
PROBLEM TO BE SOLVED: To prepare a medicine effectively usable for treating urinary calculus and preventing relapse by using an active type vitamin D as an active ingredient. SOLUTION: This therapeutic agent or relapse preventing agent comprises an active type vitamin D (preferably 1α-hydroxyvitamin D3 , 1α, 24(R)- dihydroxyvitamin D3 or 1α, 25-dihydroxyvitamin D3 ) as an active ingredient. Renal calculus is preferably cited as the urinary calculus to be applied. When the agent is used as a therapeutic agent, the daily does is preferably 100-0.01μg, more preferably 20-0.1μg and the frequency of administration is usually 1-3 times/day. When the agent is used as a preventing agent, the daily dose thereof is preferably 5-0.05μg, more preferably 0.5-0.1μg and the frequency of administration is usually 1-3 times/day. Thereby, the objective medicine can be expected.
In this study, patients with confirmed and documented preoperative non-anaemic iron deficiency (diagnosis up to 28 days before surgery in routine pre-surgery monitoring) who develop anaemia within 12 to 72 hours after start of surgery (with additional confirmation at Baseline) and for whom fast replenishment of iron stores is necessary, will be included and substituted within 24h after Screening Visit/V1. Peri- or postoperative anaemia will be assessed as soon as possible but earliest 12 h after surgery. For short term safety analysis iron in urine will be measured in the first urine after the end of i.v. administration in the first 35 patients who are eligible for analysis in each i.v. treatment group. Only those patients are eligible for whom haematuria and/or proteinuria are excluded using dip stick test. The Ferric Carboxymaltose treatment arm will be closed if a sufficient number of patients is included for safety analysis.The study will then be continued for assessment of co-primary efficacy endpoint: The effectiveness of postoperative i.v. iron substitution with Polyglucoferron compared to conventional oral iron substitution with Ferrous sulfate (treatment 28 - 35 days) to normalize Hb-values or to increase Hb-values by at least 1.5 g/dl until visit 4 will be evaluated as well as patient related outcomes, such as the decreased need for allogenic blood transfusions. In addition, the well-being of the patient will be assumed to improve after treatment using the SF36 questionnaire.
This group was composed of patients for whom after examination for symptoms of IHD and LUTS/BPH a decision was made on the necessity to perform operative treatment of BPH. TURP operation was indicated due to pronounced urination disorders which were most important amongst the patient's complaints. The patients' age varied from 59 to 77 years (mean 67.5±2.1 years).